We are developing a treatment for pancreatitis based on a protease inhibitor with enhanced pharmacokinetics and tissue distribution. Initial experiments indicate that an engineered protein lead compound can be inexpensively produced at high levels, is active in vitro, and is active in initial animal tests.
Funding
Funding Duration
July 1, 2019 - June 30, 2021
Funding level
Development
People
Principal Investigator
Pamela Silver
PhD
Elliott T. and Onie H. Adams Professor of Biochemistry and Systems Biology, Harvard Medical School
Co-PI
Daniel Heid
BSc
MSc candidate Molecular Biotechnology, Heidelberg University
Jungmin Lee
PhD
Postdoctoral Fellow, Harvard Medical School
Dominik Niopek
PhD
Group Leader, Heidelberg University, Institute for Pharmacy and Molecular Biotechnology
Katherine Redfield
BS
Graduate Student Researcher, Harvard Medical School
Jeffrey Way
PhD
Senior Staff Scientist - Synthetic and Structural Biology, Harvard University